Atazanavir Mylan, co-administered with low dose ritonavir, is indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2). Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations). The choice of Atazanavir Mylan in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient's treatment history (see sections 4.4 and 5.1).
Teva Pharmaceutical Industries Ltd. announced a proposal to acquire all of the outstanding shares of Mylan N.V. in a transaction...
Teva Pharmaceutical Industries announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary...
Mylan N.V. announced that it has officially commenced its formal offer to acquire all outstanding ordinary shares of Perrigo Company...
Mylan N.V. announced that Mylan has made a proposal to acquire Perrigo Company plc in a cash-and-stock transaction that would...
Mylan N.V. announced that the FDA has approved Mylan's Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate Injection 40 mg/mL...
Mylan N.V. and Biocon Ltd. announced that the FDA has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed...